Overview

Aim of the study. This survey aims to collect gynecologists’ opinions in order to better understand the diagnostic pathways that a patient with a suspicion of endometrial cancer would follow in European countries and US. With this knowledge, we will better focus our research and development efforts to provide clinicians with tools enabling a more rapid and objective diagnosis for all patients. 
 
Promoters. The current survey is lead by Vall Hebron University Hospital (Barcelona, Spain) in collaboration with Vall Hebron Institute of Research (VHIR) and the spin-off company MiMARK Diagnostics S.L. The collaborative consortium is financed through EU vehicle (EIT-Health Wildcard 2020), which is lead by MiMARK Diagnostics S.L. (promoter of the project).
 
Outcome. As participant of this survey, you can have access to the summary report in which the diagnostic pathways for endometrial cancer. Based on the number of responders and depth of information, this data might be compiled in a manuscript. For accessing the summary report and/or being acknowledged in the manuscript, please add your name and email address at the end of the survey (not compulsory).
 
This survey should take you aprox. 10 minutes.
Thanks for your willingness and time.

T